SLC23A2 Human Pre-designed siRNA Set A

Cat. No.: S1479660

Storage

Store at -20°C

Shipped In

Ice chest + Ice pads

Übersicht

SLC23A2 Human Pre-designed siRNA Set A contains three designed siRNAs for SLC23A2 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control. Components SLC23A2 siRNA-1: 5 nmol (HPLC) SLC23A2 siRNA-2: 5 nmol (HPLC) SLC23A2 siRNA-3: 5 nmol (HPLC) siRNA Negative Control: 5 nmol (HPLC) FAM-labeled siRNA Negative Control: 5 nmol (HPLC) GAPDH siRNA Positive Control:5 nmol (HPLC)

Specifications

Storage

Store at -20°C

Verschickt in

Ice chest + Ice pads

Dieses Produkt erfordert Kühlkettenversand. Grundversand und andere Economy-Optionen sind nicht verfügbar.

Product Line

Biologische Produkte

Application Protocols

Item-specific tested applications and dilutions: Not specified for this item; refer to CoA/Spec Sheet.

Because the Product Data provides no protocol details, please consult your transfection reagent documentation and institutional SOPs for siRNA delivery to human cells. If an application sheet accompanies this SKU, prioritize those instructions over general practices.

Biological Roles

Target gene context (literature; not an item specification):

• SLC23A2 encodes the sodium-dependent vitamin C transporter 2 (SVCT2), a high-affinity ascorbate transporter responsible for cellular uptake of reduced vitamin C in many tissues. SVCT2 supports intracellular ascorbate pools used by antioxidant systems and as a cofactor for a range of Fe2+/2-oxoglutarate–dependent dioxygenases.
• Expression: SVCT2 is widely expressed, with notable roles in metabolically active and excitable tissues. Subcellular localization is primarily the plasma membrane; splice variants and cell type can influence trafficking.
• Function in cellular physiology:
  • Maintains cytosolic and organellar ascorbate concentrations, impacting redox buffering and enzyme function.
  • Influences signaling pathways modulated by redox status and epigenetic hydroxylation reactions.

Relevance of siRNA-mediated knockdown (research use only):

• Reduces SLC23A2 transcript levels to probe the dependence of cells on sodium-coupled ascorbate transport.
• Supports mechanistic studies of ascorbate-dependent processes by enabling controlled depletion of transporter-driven uptake, with downstream measurements at the mRNA, protein, and functional transport levels.

Caveats (general):

• Functional redundancy/compensation may arise from related transporters (e.g., SLC23A1) or ascorbate recycling pathways. Design experiments with appropriate controls and consider time points capturing both immediate and adaptive responses.

Buffer Applications

Applicability: This product is an siRNA reagent; it is not a buffer. However, successful use depends on appropriate RNase-free buffers.

General buffer guidance for siRNA handling (literature; not item-specific):

• Stock preparation:
  • RNase-free water or 1× siRNA buffer (e.g., 10 mM Tris-HCl, 1 mM EDTA, pH 7.5–8.0) for initial reconstitution.
  • Prepare aliquots to avoid freeze–thaw cycles; typical working stocks 10–20 μM.
• Complex formation buffers:
  • For lipid-based transfection, use serum-free, reduced-ionic-strength media (e.g., Opti-MEM) during complexing for 5–20 minutes at room temperature; then add to cells and restore serum per reagent guidance.
• Storage buffers:
  • Slightly basic pH (7.5–8.0) with EDTA can improve stability by chelating divalent cations that catalyze RNA degradation.

Practical tips:

• Filter-sterilize buffers (0.22 μm) and confirm RNase-free status. Avoid DEPC in solutions that will contact cells unless thoroughly quenched and validated.
• For electroporation, use the manufacturer’s proprietary low-conductivity buffers; do not substitute without validation.

Item-specific buffer composition is not provided; consult the CoA/Spec Sheet or adopt institutional standard siRNA buffer protocols.

Green Alternatives

Context: siRNA workflows are largely aqueous and inherently greener than many organic-chemistry processes. Environmental impact primarily arises from plastic consumables and transfection reagents.

Greener choices and tradeoffs (general guidance):

• Delivery method selection:

  • Lipid-based transfection: High efficiency; some reagents have cytotoxic or persistent components. Choose biodegradable or lower-toxicity formulations when available.
  • Polymer-based systems (e.g., PEI variants): Cost-effective but can be more cytotoxic; use minimal effective amounts.
  • Electroporation: Solvent-free delivery; higher energy use and potential for reduced viability; no chemical waste from lipids.

• Buffer systems:

  • Use RNase-free water or minimal ionic strength buffers; avoid single-use DEPC treatment where facility systems provide certified nuclease-free water.
  • Prepare concentrated stock solutions to reduce packaging and shipping impacts.

• Waste minimization:

  • Consolidate runs to reduce plasticware use; adopt refillable reservoirs and multi-use RNase-free glass where appropriate.
  • Segregate and properly dispose of transfection waste; choose reagents with vendor-provided environmental data sheets.

Comparison (general):

• Lipid-based: High efficiency; potential cytotoxicity; chemical waste medium.
• Electroporation: Broad applicability; no lipid waste; higher instrument energy; optimization required.
• Viral delivery (not typical for synthetic siRNA): Long duration; complex biosafety and manufacturing footprint.

Note: No item-specific greener alternative is required; practices above improve sustainability without altering the siRNA itself.

Pharmaceutical Uses

Scope disclaimer: This product is labeled For research use only and is not intended for diagnostic or therapeutic use or for manufacturing purposes.

Context (general, literature):

• While synthetic siRNAs can serve as active pharmaceutical ingredients (APIs) in approved therapeutics when formulated appropriately, pre-designed research-grade siRNAs like this product are for in vitro and exploratory studies, not clinical development.
• Formulation considerations explored in research settings include:
  • Stabilizing excipients (e.g., sugars, polysorbates) for lyophilized storage; buffer systems at pH ~7–8.
  • Delivery systems (lipid nanoparticles, polymers) to enhance cellular uptake and stability, evaluated only in preclinical models under appropriate oversight.

Regulatory note:

• Pharmacopeial monographs and GMP requirements for oligonucleotides specify stringent identity, purity, and impurity profiling, sterile processing, and endotoxin control. No such claims are made for this item.

If your work requires GMP-grade or clinical-development materials, request vendor documentation for appropriate grade, quality attributes, and regulatory support. For this catalog item, limit use to laboratory research and method development.

Physical Properties

Item-specific values (from Product Data):

• Appearance: Not specified for this item; refer to CoA/Spec Sheet.
• Molecular weight/formula: Not specified for this item; refer to CoA/Spec Sheet (sequence-dependent for siRNA).

General/literature properties of siRNA duplexes (for context; not item specifications):

• Physical state: Supplied lyophilized or in aqueous solution; lyophilizates are typically white, hygroscopic solids.
• Solubility: Freely soluble in RNase-free water or buffer (e.g., 10 mM Tris, 1 mM EDTA, pH ~7.5–8.0). Avoid divalent cations without chelators due to nuclease activation.
• UV absorbance: Strong at 260 nm (A260), with strand concentration determined by sequence-specific extinction coefficients (literature). Typical calculation uses A260 = 1.0 ≈ 40 μg/mL for ssRNA; duplex values differ slightly.
• Stability: Sensitive to RNases; chemically stable when dry, protected from moisture, and stored frozen. Repeated freeze–thaw should be minimized.
• pH sensitivity: Stable near neutral to slightly basic pH; acidic conditions can promote depurination/degradation over time.
• Thermal behavior: Duplex melting temperature (Tm) is sequence- and salt-dependent; 19–21 bp siRNA often exhibit Tm in the 60–85 °C range in physiological salt (literature), but exact Tm must be calculated per sequence.

Note: Exact duplex length, modifications, extinction coefficients, and concentrations for this item are not specified; consult the item’s CoA/Spec Sheet for definitive values.

Quality and Grades

Item-specific grade/purity: Not specified for this item; refer to CoA/Spec Sheet.

How to interpret siRNA quality (general guidance):

• Purification levels:
  • Desalted or cartridge-purified: Adequate for many cell-culture knockdown experiments; may contain minor truncated species.
  • HPLC-purified: Higher purity with reduced n-1 species; often preferred for sensitive cells, in vivo-like assays, or when low off-target risk is desired.
  • PAGE-purified: Very high strand length homogeneity; used when maximum precision is required.
• Strand stoichiometry: Equimolar annealing of sense/antisense strands is critical. Vendors may supply pre-annealed duplexes; otherwise, annealing protocols ensure correct duplex formation.
• Modifications and stabilizers: Chemical modifications (e.g., 2′-O-Me, 2′-F, phosphorothioates, terminal phosphates) can improve stability or potency but may alter specificity. Presence/absence for this item is not specified; refer to CoA.
• QC metrics you may expect on a CoA (examples; not item-specific):
  • OD260 and calculated nmol, analytical HPLC trace, mass spec confirmation, residual solvent/salt profile, sterile filtration status, endotoxin/bioburden (if applicable).

Practical note: When selecting grade, balance cell sensitivity, required knockdown magnitude/duration, and downstream readouts (e.g., RNA-seq) where purity and modification state can influence off-target signatures.

Reaction and Applications

Primary application (item scope): Transient RNA interference (RNAi)-mediated knockdown of human SLC23A2 in cultured cells for research use only.

• Mechanistic overview (literature):

  • Exogenous siRNA duplexes are incorporated into the RNA-induced silencing complex (RISC). The antisense (guide) strand directs sequence-specific binding to SLC23A2 mRNA, leading to Argonaute-catalyzed endonucleolytic cleavage and degradation.
  • Effective knockdown usually appears 24–72 h post-transfection, with duration of 3–7 days depending on cell division and siRNA stability.

• Use cases:

  • Functional genomics: Assess SLC23A2’s contribution to ascorbate transport, redox homeostasis, and related cellular processes.
  • Pathway mapping: Interrogate downstream transcriptional or metabolic changes upon SLC23A2 silencing.
  • Assay development: Establish target-engagement controls, validate antibody or probe specificity by loss-of-signal readouts.

• Practical considerations (general):

  • Select a robust transfection method compatible with the cell type (lipid-based for many lines; electroporation for hard-to-transfect cells).
  • Include controls: non-targeting siRNA, positive knockdown control (e.g., PLK1 in dividing cells), and mock-transfected cells.
  • Optimize dose: Typical working concentrations range from 5–50 nM (literature), titrating to minimize off-targets while maintaining knockdown.
  • Quantify outcomes: Use qRT-PCR for mRNA reduction and immunoblot/flow for protein-level effects; align sampling times with protein turnover.

Manufacturer Applications: No additional item-specific application notes were provided; the above expands on standard siRNA usage targeting SLC23A2.

Reaction Conditions

Here, “reaction” refers to cell transfection and gene silencing, not a chemical transformation.

General transfection conditions (literature; adjust per cell type and reagent):

• Cell density: Plate cells to reach ~30–70% confluence at transfection for adherent lines; suspension cells at vendor-recommended densities.
• siRNA dose: Common working range 5–50 nM final; titrate to find the minimal effective concentration to reduce off-targets.
• Complexing: Mix siRNA with transfection reagent in serum-free medium (e.g., Opti-MEM), incubate 5–20 minutes at room temperature to allow complex formation.
• Incubation: Add complexes to cells and incubate 4–6 hours before optionally replacing medium; some reagents permit no-change protocols.
• Temperature/atmosphere: 37 °C, 5% CO2 for mammalian cells unless the cell model requires otherwise.
• Readouts: mRNA reduction typically detectable by 24 h; maximal knockdown often at 48–72 h. Protein-level effects lag with protein half-life.

Controls and replication:

• Include non-targeting siRNA, positive control siRNA, and mock transfection.
• Perform biological triplicates and technical duplicates for quantitative assays (qRT-PCR, Western blot).

Note: Exact recommended conditions for this specific item are not provided in the Product Data; refer to the transfection reagent manufacturer and your cell-line SOPs.

Safety and Handling

GHS classification and hazard statements (item-specific):

• Signal Word: Not specified for this item; refer to SDS.
• H-Statements: Not specified for this item; refer to SDS.
• GHS Classification/Pictograms: Not specified for this item; refer to SDS.

General laboratory safety for siRNA (literature/guidance; defer to SDS):

• Expected hazards: Synthetic siRNA oligonucleotides are generally regarded as low hazard. Principal risks are from trace contaminants (salts, solvents) and biological handling (transfection reagents may be irritants) rather than the oligonucleotide itself.
• PPE: Lab coat, safety glasses, and disposable nitrile gloves. Change gloves frequently to minimize RNase transfer.
• RNase control: Use certified RNase-free plasticware, filter tips, and solutions. Clean work surfaces with RNase decontamination solutions. Avoid touching tube rims and keep tubes capped.
• Incompatibilities: Avoid nucleases (biological contamination), strong acids/bases, and high temperatures that accelerate RNA hydrolysis. Do not mix with divalent metal ions without chelators (EDTA) if nuclease contamination is possible.
• First aid (general): Skin/eye contact with buffers or transfection reagents—rinse with water for at least 15 minutes; seek medical advice if irritation persists. Ingestion/inhalation—seek medical attention according to SDS guidance.
• Waste: Dispose of RNA-containing materials and transfection reagents according to institutional biosafety and chemical waste policies. Decontaminate with appropriate agents (e.g., RNase inactivation solutions) before discard when required.

Solvent Selection

Applicability: siRNA is handled in aqueous, nuclease-free solutions rather than organic solvents.

• Recommended solvents/buffers (general, literature):
  • RNase-free water: Maximizes compatibility; adjust pH with RNase-free Tris if needed.
  • 1× siRNA buffer: Often 10 mM Tris-HCl, 1 mM EDTA, pH 7.5–8.0; EDTA chelates divalent cations to reduce nuclease activity.
  • Low-salt buffers (e.g., 10 mM HEPES, pH 7.4) for complex formation with cationic lipids.
• Avoid:
  • Strongly ionic buffers or high Mg2+/Ca2+ during storage (can promote nuclease activity).
  • Organic solvents (e.g., ethanol, DMSO) as primary diluents for siRNA stocks—these can destabilize duplexes and affect transfection; trace carryover from precipitation is acceptable if removed.
• Miscibility and polarity (general): siRNA is highly polar and only soluble in water and aqueous buffers; insoluble in nonpolar organic solvents.
• Practical tips:
  • Prepare a concentrated stock (e.g., 10–20 μM; literature) in RNase-free water, then dilute into cell-culture medium during transfection.
  • For lipid-based transfection, form complexes in serum-free medium (Opti-MEM or equivalent), then add to cells; introduce serum after complexing as permitted by the reagent.

Note: Exact buffer composition and concentration for this item are not specified; consult the product CoA/Spec Sheet or your in-house protocol.

Storage and Reconstitution

Item-specific storage and shipping (from Product Data):

• Storage Conditions: Store at −20 °C.
• Shipped In: Ice chest + Ice pads.

Additional handling notes (general guidance; not item-specific specifications):

• Upon receipt: If lyophilized, allow the sealed vial to equilibrate to room temperature in a desiccated environment before opening to prevent condensation. If in solution, keep on ice and transfer promptly to −20 °C storage.
• Reconstitution: Not specified for this item; refer to CoA/Spec Sheet. General practice is to dissolve in RNase-free water or siRNA buffer to a convenient stock (e.g., 10–20 μM), vortex gently, and briefly spin down.
• Aliquoting: Prepare single-use aliquots in RNase-free tubes to avoid repeated freeze–thaw cycles.
• Short-term storage: 2–8 °C for up to a few days once in solution (literature); minimize time at ambient temperature.
• Long-term storage: −20 °C (as specified) or −80 °C for maximal stability. Avoid frost-free freezers that warm during defrost cycles.
• Freeze–thaw: Limit cycles; thaw on ice and mix gently. Do not heat.

Note: Exact concentration, buffer composition, and any stabilizers for this item are not provided; consult the CoA/Spec Sheet for definitive instructions.

Structure and Identity

Brief description: SLC23A2 Human Pre-designed siRNA Set A is a pool of small interfering RNA (siRNA) duplexes designed to transiently silence the human SLC23A2 gene in cultured cells for research applications.

• Item-specific identifiers from Product Data:

  • SKU: S1479660
  • Name: SLC23A2 Human Pre-designed siRNA Set A
  • Target: SLC23A2 (human)
  • CAS: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Formula: Not specified for this item; refer to CoA/Spec Sheet.
  • Molecular Weight: Not specified for this item; refer to CoA/Spec Sheet.
  • SMILES / InChIKey: Not applicable to siRNA pools; sequence-based macromolecules. Not specified for this item; refer to CoA/Spec Sheet.

• Structural features (general, literature):

  • siRNA are double-stranded RNA duplexes typically ~19–27 base pairs with 2-nt 3′ overhangs (e.g., dTdT) to facilitate RISC loading.
  • Each strand comprises ribonucleotides with a ribose 2′-OH and phosphodiester (or modified) backbone; optional chemical stabilizations (e.g., 2′-O-Me, 2′-F, phosphorothioates) may be used by some vendors. Specific modifications for this item: Not specified for this item; refer to CoA/Spec Sheet.
  • Orientation: sense strand is homologous to target mRNA; antisense (guide) strand is complementary and directs RISC-mediated cleavage.

• 2D description in words (general):

  • Two antiparallel RNA strands forming an A-form helix with Watson–Crick base pairing (A–U, G–C), capped by short 3′ overhangs; terminal 5′-phosphate on the guide strand is often required for optimal RISC activity (literature).

Synthetic Utility

Not a classical small-molecule building block: As a sequence-defined siRNA duplex, this product is not typically employed as a reagent or intermediate in organic synthesis.

Relevance to chemical biology (general, literature):

• Tool compound for target validation: siRNA knockdown complements small-molecule inhibition to dissect on-target vs off-target effects in chemical probe development.
• Phenotypic screening: Pairing siRNA-mediated gene silencing with compound libraries helps map compound mechanism-of-action via genetic interaction profiling.
• Pathway dissection: Use siRNA to modulate nodes within metabolic or signaling pathways, then apply chemoproteomic or metabolomic readouts.

If your workflow requires covalent conjugation (e.g., fluorophores, biotin, delivery ligands), order sequence-customized oligos with defined functional groups. This item’s modification state is not specified; refer to CoA/Spec Sheet if modifications are present.

Target Specificity

Item-specific target information (from Product Data only):

• Product type: Pre-designed siRNA Set A
• Target gene: SLC23A2
• Species: Human

No additional sequence details, guide strand information, or validated off-target analysis are provided in the Product Data. For sequence-level specificity, predicted target sites, or validation datasets, please refer to the CoA/Spec Sheet or contact technical support with the SKU S1479660.

Häufig gestellte Fragen

How should this product be stored?

Store at ?20 °C. Freezer storage is required to maintain the specified shelf life.

How is this product shipped?

This product ships in an insulated container with ice pads. Unpack on arrival and transfer it to the storage condition stated above.

What documentation is provided?

Available product documentation, including Certificates of Analysis (COA), Safety Data Sheets (SDS), and specification sheets, is shown in the product document area. Document availability and access follow the current site policy.